Equal Conversion to Focalin from Concerta 36 mg
For a patient taking Concerta 36 mg daily, convert to Focalin (dexmethylphenidate) 18 mg daily, using a 2:1 ratio (methylphenidate to dexmethylphenidate).
Conversion Rationale
The conversion from racemic methylphenidate (Concerta) to dexmethylphenidate (Focalin) follows a 2:1 ratio based on the pharmacologically active d-isomer content. Since dexmethylphenidate contains only the active d-enantiomer while racemic methylphenidate is a 50:50 mixture of d- and l-isomers, half the dose of dexmethylphenidate provides equivalent therapeutic effect 1.
Specific Conversion for 36 mg Concerta:
- Concerta 36 mg daily → Focalin 18 mg daily
- This can be administered as either:
- Focalin immediate-release: 9 mg twice daily
- Focalin XR (extended-release): 18 mg once daily in the morning
Formulation Considerations
Extended-release formulations are preferred for once-daily dosing, improved compliance, and reduced stigma from in-school dosing 2. Focalin XR utilizes bimodal release technology (50% immediate, 50% delayed at 4 hours) that mirrors the pharmacokinetic profile of twice-daily immediate-release dosing 1.
Research demonstrates that 20 mg Focalin XR is bioequivalent to 40 mg Concerta in terms of d-methylphenidate exposure, confirming the 2:1 conversion ratio 3, 1. The bimodal release formulation provides symptom control for up to 12 hours post-dosing 3.
Dosing Guidelines
According to available guidelines, dexmethylphenidate dosing parameters are 4:
- Starting dose: 2.5-5 mg daily or twice daily
- Dose range: 5-20 mg/day, usually divided as twice daily
- Maximum recommended dose: 20 mg/day
For your patient converting from 36 mg Concerta, the 18 mg daily dexmethylphenidate dose falls within the therapeutic range but approaches the upper limit. This is appropriate given the established therapeutic response to the equivalent methylphenidate dose.
Titration and Monitoring
Start with the calculated conversion dose rather than titrating from lower doses, since the patient has already demonstrated tolerance and response to the equivalent methylphenidate dose 5. However, monitor closely for:
- Common side effects: Decreased appetite, insomnia, irritability (occur in 6-19% of patients) 6
- Cardiovascular parameters: Blood pressure and heart rate at baseline and follow-up
- Efficacy: Symptom control throughout the day, particularly comparing morning vs. afternoon/evening coverage
Important Caveats:
Focalin XR may have faster onset but potentially shorter duration compared to Concerta. One comparative study found that while dexmethylphenidate ER 20 mg had more rapid onset and greater morning effect versus methylphenidate ER 36 mg, the racemic formulation retained greater effect at the end of the 12-hour day 3. If breakthrough symptoms occur in late afternoon/evening, consider:
- Adding a small immediate-release dexmethylphenidate dose (2.5-5 mg) in late afternoon
- Alternatively, returning to Concerta if extended duration is clinically necessary
The 2:1 conversion is based on pharmacokinetic equivalence, but individual response varies. Some patients may require dose adjustment based on clinical response and tolerability. The dose-proportional pharmacokinetics of dexmethylphenidate formulations facilitate straightforward titration if needed 7.
Safety profile is comparable between formulations, with no unexpected adverse events in long-term studies up to 12 months 6. Both medications carry similar warnings regarding abuse potential, cardiovascular risks, and psychiatric adverse effects 5.